Xalkori
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2250 Perimeter Park Dr Ste 300, Morrisvi...Phone Number
(877) 744-5675Website
www.xalkori.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Xalkori
Learn about XALKORI® (crizotinib), an Rx option for ALK+ or ROS1+ metastatic non-small cell lung cancer (mNSCLC). See risks & benefits.Explore more
Popular SearchesXalkoriPfizer IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xalkori your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Xalkori launches new products
Click to see if Xalkori had a recent Job posting/layoffs
Check if Xalkori has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xalkori has new funding data
Check out if Xalkori is spiking on competitors!
Xalkori, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Xalkori recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Xalkori
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Xalkori as Masked Content
Find 2 more new buyers
Compare Similar Companies to Xalkori
Compare insights from companies similar to Xalkori, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Xalkori
$5.6M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Xalkori is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xalkori is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xalkori.
Xalkori Tech Stack
A closer look at the technologies used by Xalkori
Xalkori News & Media
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. “Improving outcomes for patients is the central focus of why we develop and delive
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xalkori
Sign Up For FreeTo access detailed company insights
Learn about XALKORI® (crizotinib), an Rx option for ALK+ or ROS1+ metastatic non-small cell lung cancer (mNSCLC). See risks & benefits.... Read More
